PO-40 - Real-life use of non-vitamin k antagonist oral anticoagulants in patients with cancer associated venous thromboembolism: data from a prospective cohort. Issue 140 (April 2016)

• Record Type: Journal Article
• Authors: Mancuso, A.; Vedovati, M.C.; Pierpaoli, L.; Paliani, U.; Conti, S.; Filippucci, E.; Ascani, A.; Radicchia, S.; Galeotti, G.; Agnelli, G.; Becattini, C.
• Is Part Of: Thrombosis research. Issue 140(2016)Supplement 1
• Page Start: S191
• Publication Date: 2016-04
• Subjects: Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/S0049-3848(16)30173-6
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract : Introduction: Cancer associated thrombosis (CAT) has an increased risk of recurrent venous thromboembolism (VTE). Type, stage of cancer and chemotherapy (CHT) influence thromboembolic risk. The use of novel oral anticoagulants (NOACs) is controversial in patients with CAT. Aim: The aim of this study is to assess mortality, recurrent VTE and bleeding complications in patients with CAT and in patients without cancer receiving NOACs. Materials and Methods: Consecutive patients with acute objectively confirmed VTE receiving NOACs within 1 month from diagnosis are included from September 2013 in an ongoing prospective cohort study. Characteristics of patients and outcome are reported according to the presence of CAT. Chi-squared test and Student' t-test are used. Results: As for November 10 th 2015, 472 patients were included in the study: 78 with CAT (16.5%). Lung, breast, gastrointestinal and genitourinary cancer was observed in 16%, 24%, 20% and 24% of patients with CAT, respectively. 31 patients with CAT (40%) were on CHT or radiotherapy (RT). 10 patients with CAT (13%) had at least an additional risk factor for VTE (4 had a CVC related thrombosis) and 34 (43.5%) were inpatients. Baseline characteristics of patients with and without CAT are reported in the Table. Pulmonary embolism was index VTE in 152 patients: 24.4% of patients with CAT and in 33.8% of those without cancer (p = 0.10). DVT only was present in 320 patients and 78 had both DVT and PE. Among NOACs patients, 312 (66%) received initial loading dose: 61% of those with CAT and 67% without. 53 (11%) received reduced maintenance doses (10% with CAT, 11% without). As for nowadays, 272 patients had at least 3 months of follow-up, the mean follow-up being 8.6 months. 20 patients died (7.3%): 17 were cancer related deaths. Non cancer related death occurred in 1 patient with CAT (2%) and in 2 patients without (0.9%). No fatal bleedings or fatal VTE recurrences occurred. Patients recruitment and follow-up is currently ongoing aimed at assessing mortality, recurrent VTE and bleeding complications. Updated results on clinical outcomes will be presented at the congress. Table CAT pts (78) Non-CAT pts (394) P Age, mean ± SD 71 ± 14 66 ± 17 0.02 Male, % 50% 50% 1.00 BMI, mean ± SD 26 ± 5 28 ± 5 0.008 CrCl < 50 ml/min, % 12.7% 7.4% 0.16 DVT, % Upper arm 11.5% 1.3% < 0.001 Caval/iliac 15.8% 12.2% 0.42 Femoral/popliteal 48.7% 62.4% 0.02 Distal 9.5% 7.7% 0.50 PE, % Central 36.8% 53.4% 0.18 Lobar 31.6% 19.5% 0.23 Segm/subsegm 31.6% 27.1% 0.68 Conclusions: Patients with CAT receiving NOACs are treated as patients without CAT in terms of use of loading doses and maintenance treatment. Upper arm thrombosis is more frequently involved in CAT patients and proximal lower vein in patients without CAT. Non cancer related mortality was higher in CAT patients but no fatal recurrences or fatal bleedings were observed so far.